Blueprint Medicines Corporation is anticipating a gradual ramp in sales for Ayvakit (avapritinib) in indolent systemic mastocytosis (ISM), starting with those who are already diagnosed, but it sees an opportunity to reach blockbuster sales if it can address even half of the overall ISM population.
On 22 May, the US Food and Drug Administration approved Ayvakit for ISM, making it the first and only drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?